- Home
- ARMK vs EXEL Comparison
ARMK vs EXEL Comparison
Compare ARMK & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARMK | EXEL |
|---|---|---|
| Founded | 1959 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 11.1B |
| IPO Year | 2013 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ARMK | EXEL |
|---|---|---|
| Price | $38.54 | $41.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 22 |
| Target Price | ★ $46.50 | $46.05 |
| AVG Volume (30 Days) | ★ 2.6M | 2.5M |
| Earning Date | 02-10-2026 | 02-10-2026 |
| Dividend Yield | ★ 1.25% | N/A |
| EPS Growth | 23.23 | ★ 53.55 |
| EPS | 1.22 | ★ 2.38 |
| Revenue | ★ $18,506,299,000.00 | $2,288,218,000.00 |
| Revenue This Year | $8.64 | $9.65 |
| Revenue Next Year | $5.93 | $12.03 |
| P/E Ratio | $31.55 | ★ $17.40 |
| Revenue Growth | 6.35 | ★ 9.93 |
| 52 Week Low | $29.92 | $32.38 |
| 52 Week High | $44.49 | $49.62 |
Technical Indicators
Market Signals| Indicator | ARMK | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 50.42 | 37.66 |
| Support Level | $38.20 | $43.00 |
| Resistance Level | $39.16 | $45.37 |
| Average True Range (ATR) | 0.73 | 1.49 |
| MACD | -0.08 | -0.38 |
| Stochastic Oscillator | 30.43 | 13.47 |
Price Performance
Historical ComparisonAbout ARMK Aramark
Aramark, founded in 1936 and headquartered in Philadelphia, Pennsylvania, operates as a food service company providing facility management and workplace solutions. The company primarily generates revenue from its North American food and support services segment, serving various clients including schools, healthcare facilities, and entertainment venues.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.